- Home
- NAMS vs MKTX Comparison
NAMS vs MKTX Comparison
Compare NAMS & MKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAMS | MKTX |
|---|---|---|
| Founded | 2019 | 2000 |
| Country | Netherlands | United States |
| Employees | 100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.6B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | NAMS | MKTX |
|---|---|---|
| Price | $34.72 | $116.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $46.75 | ★ $204.88 |
| AVG Volume (30 Days) | ★ 1.1M | 796.2K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.94% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.20 |
| Revenue | N/A | ★ $397,471,000.00 |
| Revenue This Year | $17.96 | $10.14 |
| Revenue Next Year | $540.65 | $7.22 |
| P/E Ratio | ★ N/A | $52.05 |
| Revenue Growth | N/A | ★ 7.45 |
| 52 Week Low | $20.53 | $108.75 |
| 52 Week High | $42.21 | $219.18 |
Technical Indicators
Market Signals| Indicator | NAMS | MKTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.15 | 42.28 |
| Support Level | $33.83 | $111.02 |
| Resistance Level | $37.27 | $125.21 |
| Average True Range (ATR) | 1.53 | 4.54 |
| MACD | 0.56 | 0.96 |
| Stochastic Oscillator | 76.74 | 48.18 |
Price Performance
Historical ComparisonAbout NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
About MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.